Lilly Endowment Inc, an insider of Eli Lilly and Co (LLY), executed a significant sale on November 16, 2025, offloading 92,872,191 shares at a price of $1,031.53 per share. The total value of this transaction amounted to approximately $95.8 billion.
Following this sale, Lilly Endowment Inc retains 92,872,191 shares of the company. Insider transactions like this one are required to be reported to the SEC, providing transparency into the actions of company executives and board members.
Such decisions reflect various factors, including diversification, tax planning, or personal financial needs. While large sales may attract attention, they do not inherently signal negative sentiment toward the company. Investors are encouraged to consider insider activity in the context of broader market trends and financial performance.
Eli Lilly and Co, headquartered in Indianapolis, Indiana, is a major player in the pharmaceuticals industry, employing 47,000 full-time staff. The company focuses on the discovery, development, manufacture, and sale of pharmaceutical products, with offerings in cardiometabolic health, oncology, immunology, and neuroscience. As of November 18, 2025, Eli Lilly boasts a market capitalization of $965.9 billion, a P/E ratio of 52.46, and an EPS of 20.45. The company's upcoming earnings report is scheduled for April 28, 2026, with an estimated EPS of $7.16 and revenue of $17.1 billion.